Navigation Links
Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
Date:1/18/2011

inties, which include, without limitation, risks related to the uncertainty of the FDA approval process and other regulatory requirements, and the timing of completion of the steps necessary for resubmission of the NDA for AZ-004.  Alexza may be unsuccessful in resolving the issues in the CRL and it may never receive marketing approval for AZ-004 or any of its product candidates.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.", "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.", and "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.".  Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
2. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
3. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
4. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
7. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
8. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
9. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
10. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
11. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... virus infections, today announced that Jonathan P. ... of Finance, a newly created role.  Mr. Freve ... including financial planning and reporting, accounting and risk ... , President and CEO. Mr. ...
(Date:2/26/2015)... , Feb. 26, 2015 The ... America is estimated at 2.4 billion ... that population growth, government insurance, newly insured patients ... the region and will continue to propel demand.  The ... torresearch into the market and interviews with IVD ...
(Date:2/26/2015)... 26, 2015 Columbia Laboratories, Inc. (Nasdaq: ... a specialty pharmaceutical company focused on the development ... a Phase II clinical trial for COL-1077, a ... pipelle-directed endometrial biopsy in the second quarter of ... submission feedback from the United States Food and ...
Breaking Medicine Technology:Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 3
... SHANGHAI, July 19, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... biotechnology and medical device R&D outsourcing company with operations ... it will release financial results for the second quarter ... on Wednesday, August 10, 2011 (which will be Thursday ...
... 2011 ,   - ... Aims to Improve Overall Interdisciplinary Care , and Transform Patient ... CPM Resource Center (CPM), a leader in developing,clinical decision support ... Services, a not-for-profit,health system committed to providing services to communities ...
Cached Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release 2Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 2Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 3Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 4
(Date:2/26/2015)... 26, 2015 Imagine a day without access ... proper baths and there was no one to help. For ... was today. In 2015, more than 2.5 billion people will ... , A new initiative led by Nevada’s Desert ... numbers, focusing specifically on women – who often bear the ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The COR ... Topical BioMedics, Inc., Rhinebeck, NY, to offer customers a ... topical biomedicine formulas that safely and effectively address muscle, ... new division of Vets Access LLC, Montrose, MI, that ... healing products. , Topical BioMedics is a research and ...
(Date:2/26/2015)... Scotch Plains, NJ (PRWEB) February 26, 2015 ... celebrating the reopening of their newly renovated office in ... Mann, the Reproductive Science Center of New Jersey’s physicians, ... outstanding work and patient care in the areas of ... is commended for having excellent success rates and providing ...
(Date:2/26/2015)... Linda, CA (PRWEB) February 26, 2015 ... , “Diversity of extracellular vesicles and their cargo in ... extracellular vesicles and their relevance for cell-to-cell communication. The ... live March 4, 2015 at 8:00am PT. , Every ... extracellular vesicles (EVs) , often called “exosomes” or ...
(Date:2/26/2015)... 2015 Body Well Therapy, a multi-regional provider ... delivering high quality mobile massage services to individuals ... across the United States. The company has experienced steady growth ... as it sets its sights on additional major market expansion ... services. , “We’ve come a long way since our founding ...
Breaking Medicine News(10 mins):Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 3Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 2Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 3
... of medicine at Boston University School of Medicine (BUSM), ... New England Region 2011 Clinician Investigator Award for his ... presented to Rose at the Society,s New England Regional ... promote research and education that aims at improving healthcare ...
... patients to find novel genetic changes at the root of ... workhorse a mouse. By sequencing the genome of ... Medicine in St. Louis have uncovered mutations that also drive ... a mouse cancer genome, and their research is reported online ...
... helps you say yes to NO , ,Disorders of ... world, and can lead to heart attacks, strokes and even ... and angioplasty, themselves induce vascular injury, after which the cells ... limits blood flow. Nitric oxide (NO) is an important molecule ...
... a big way, marketing products as more sustainably ... proliferation of green cleaning products, office supplies, packaging ... 80,000 chemicals with uncertain health and environmental impacts ... with more discovered every day. "Green ...
... -- A new study helps explain how some lung ... at the Massachusetts General Hospital Cancer Center analyzed tumor ... the leading cause of cancer death worldwide, and identified ... also confirmed resistance-related genetic changes identified in previous studies. ...
... Montreal, March 23, 2011 Researchers at Concordia University ... as they occur a new technique that may ... paper, "A Novel Morphology-Based Classifier for Automatic Detection of ... Engineering in Medicine and Biology Society, documents the very ...
Cached Medicine News:Health News:Mouse cancer genome unveils genetic errors in human cancers 2Health News:Mouse cancer genome unveils genetic errors in human cancers 3Health News:Mouse cancer genome unveils genetic errors in human cancers 4Health News:JCI online early table of contents: March 23, 2011 2Health News:JCI online early table of contents: March 23, 2011 3Health News:JCI online early table of contents: March 23, 2011 4Health News:JCI online early table of contents: March 23, 2011 5Health News:JCI online early table of contents: March 23, 2011 6Health News:JCI online early table of contents: March 23, 2011 7Health News:JCI online early table of contents: March 23, 2011 8Health News:JCI online early table of contents: March 23, 2011 9Health News:JCI online early table of contents: March 23, 2011 10Health News:Conference highlights UC Berkeley's unique approach to green chemistry 2Health News:Conference highlights UC Berkeley's unique approach to green chemistry 3Health News:Conference highlights UC Berkeley's unique approach to green chemistry 4Health News:Conference highlights UC Berkeley's unique approach to green chemistry 5Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:New way to detect epileptic seizures 2
... first wavefront aberrometer specifically designed to meet ... Practitioner. Utilizing a proprietary, non Hartmann-Shack technology ... accurately measures high order aberrations (3rd-6th order), ... to arrive at a fully optimized prescription ...
... Industrial Laboratories, Inc. specializes in state-of-the-art ... and laboratory specular microscopes, digital video ... digital upgrade package. Our software incorporates ... data correlation with rapid image sequence ...
... friendly computerized medical record system whose goal ... of the practice as well as improve ... provides clinical templates for commonly presenting problems ... contains an exhaustive database to cover rare ...
... applanation tonometer is designed to fit ... or most "Zeiss" style models. This ... intra-ocular pressure readings. The instrument stays ... and the prism is swung down ...
Medicine Products: